Literature DB >> 26521888

Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23.

Shweta Bansal, Khaled Khazim, Rajeev Suri, DeAndra Martin, Sherry Werner, Paolo Fanti.   

Abstract

Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting, hypophosphatemia, and osteomalacia. Fibroblast growth factor (FGF)-23, a phosphatonin i.e., phosphaturia-promoting hormone, is commonly implicated in the pathogenesis of TIO. However, very limited information is available about the circulating levels and clinical significance of other phosphatonins that are expressed by TIO-associated tumors. In addition, identification of the primary tumor constitutes a frequent major challenge in the management of TIO. Here, we report a patient with the clinical diagnosis of TIO with elevated blood levels of the phosphatonins FGF-23 and FGF-7; and extensive but unrewarding radiological search for the primary tumor. In selective venous sampling, both FGF-23 and FGF-7 displayed highest concentrations in the left femoral and iliac veins; although lateralization was much more pronounced for FGF-7 than FGF-23. This laboratory finding allowed us to focus on the left lower extremity as the likely location of the primary tumor. Our case is the first to show that FGF-7 can be analyzed in the circulation and used to assist in the diagnosis and localization of TIO-associated tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26521888     DOI: 10.5414/CN108596

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  "Slow and steady wins the race": the importance of perseverance in the management of oncogenic osteomalacia.

Authors:  Maria Manara; Luigi Sinigaglia
Journal:  Endocrine       Date:  2016-11-29       Impact factor: 3.633

2.  Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)2D and normal FGF7 concentrations characterize patients with CKD.

Authors:  Kittrawee Kritmetapak; Louis Losbanos; Taylor E Berent; Susan L Ashrafzadeh-Kian; Alicia Algeciras-Schimnich; Jolaine M Hines; Ravinder J Singh; Rajiv Kumar
Journal:  BMC Nephrol       Date:  2021-03-30       Impact factor: 2.388

3.  The Foot That Broke Both Hips: A Case Report and Literature Review of Tumor-Induced Osteomalacia.

Authors:  Sara Beygi; Alfred Denio; Tarun S Sharma
Journal:  Case Rep Rheumatol       Date:  2017-09-14

4.  Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia.

Authors:  Michael P Whyte; Fan Zhang; Deborah Wenkert; Steven Mumm; Theresa J Berndt; Rajiv Kumar
Journal:  Bone       Date:  2020-02-26       Impact factor: 4.398

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.